Key Takeaways on Enhancing Outcomes for mNSCLC Without Targetable Driver Mutations

This newest approval for amivantamab is the second approval in 6 months for the EGFR and MET bispecific antibody.

Measures of systemic inflammation used for the liver, including C-reactive protein-albumin ratio and modified Glasgow prognostic score, demonstrated prognostic value in non–small cell lung cancer (NSCLC).

In part 1 of our interview with David P. Carbone, MD, PhD, The Ohio State University, he addressed why it is important to conduct biomarker testing in both lung cancer overall and non–small cell lung cancer more specifically.

Patients with non-small cell lung cancer (NSCLC) can use lazertinib in combination with amivantamab as a first-line treatment.

This investigation was conducted among older, frail patients, a population typically underrepresented in clinical trials.

David P. Carbone, MD, PhD, director of the thoracic oncology center at The Ohio State University in Columbus, discusses the importance of biomarker testing in both lung cancer overall and non–small cell lung cancer specifically.